High absolute basophil count is a powerful independent predictor of inferior overall survival in patients with primary myelofibrosis

References

• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016 May 19;127(20):2391–2405. doi:10.1182/blood-2016-03-643544. PubMed PMID: 27069254. doi: 10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Buschle M, Janssen JW, Drexler H, et al. Evidence for pluripotent stem cell origin of idiopathic myelofibrosis: clonal analysis of a case characterized by a N-ras gene mutation. Leukemia. 1988 Oct;2(10):658–660. PubMed PMID: 3050294.
   PubMed Web of Science ®Google Scholar
• Tefferi A, Lasho TL, Finke CM, et al. CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons. Leukemia. 2014 Jul;28(7):1472–1477. doi:10.1038/leu.2014.3. PubMed PMID: 24402162. doi: 10.1038/leu.2014.3
   PubMed Web of Science ®Google Scholar
• Mesa RA, Niblack J, Wadleigh M, et al. The burden of fatigue and quality of life in myeloproliferative disorders (MPDs): an international internet-based survey of 1179 MPD patients. Cancer. 2007 Jan 01;109(1):68–76. doi:10.1002/cncr.22365. PubMed PMID: 17123268. doi: 10.1002/cncr.22365
   PubMed Web of Science ®Google Scholar
• Hultcrantz M, Kristinsson SY, Andersson TM, et al. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol. 2012 Aug 20;30(24):2995–3001. doi:10.1200/JCO.2012.42.1925. PubMed PMID: 22802311; PubMed Central PMCID: PMC3417050. doi: 10.1200/JCO.2012.42.1925
   PubMed Web of Science ®Google Scholar
• Cervantes F, Dupriez B, Pereira A, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood. 2009 Mar 26;113(13):2895–2901. doi:10.1182/blood-2008-07-170449. PubMed PMID: 18988864. doi: 10.1182/blood-2008-07-170449
   PubMed Web of Science ®Google Scholar
• Passamonti F, Cervantes F, Vannucchi AM, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood. 2010 Mar 4;115(9):1703–1708. doi:10.1182/blood-2009-09-245837. PubMed PMID: 20008785. doi: 10.1182/blood-2009-09-245837
   PubMed Web of Science ®Google Scholar
• Gangat N, Caramazza D, Vaidya R, et al. DIPSS plus: a refined dynamic international prognostic scoring system for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol. 2011 Feb 1;29(4):392–397. doi:10.1200/JCO.2010.32.2446. PubMed PMID: 21149668. doi: 10.1200/JCO.2010.32.2446
   PubMed Web of Science ®Google Scholar
• Shah S, Mudireddy M, Barraco D, et al. Marked elevation of serum lactate dehydrogenase (LDH) in primary myelofibrosis: clinical and prognostic correlates. Blood. 2016;128(22):3113–3113.
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Pejsa V, Jaksic O, et al. The degree of anisocytosis predicts survival in patients with primary myelofibrosis. Acta Haematol. 2016;136(2):98–100. doi:10.1159/000445247. PubMed PMID: 27189016. doi: 10.1159/000445247
   PubMed Web of Science ®Google Scholar
• Shah S, Mudireddy M, Lasho TL, et al. Monocytosis is a powerful and independent predictor of shortened overall and leukemia-free survival in primary myelofibrosis. Blood. 2016;128(22):4249–4249.
   Web of Science ®Google Scholar
• Juhlin L. Basophil and eosinophil leukocytes in various internal disorders. Acta Med Scand. 1963;174(2):249–255. doi: 10.1111/j.0954-6820.1963.tb07918.x
   PubMedGoogle Scholar
• Spiers AS, Bain BJ, Turner JE. The peripheral blood in chronic granulocytic leukaemia. Study of 50 untreated Philadelphia-positive cases. Scand J Haematol. 1977 Jan;18(1):25–38. PubMed PMID: 265093. doi: 10.1111/j.1600-0609.1977.tb01474.x
   PubMedGoogle Scholar
• Gilbert HS. Myelofibrosis revisited: characterization and classification of myelofibrosis in the setting of myeloproliferative disease. Prog Clin Biol Res. 1984;154:3–17.
   PubMedGoogle Scholar
• Arnalich F, Lahoz C, Larrocha C, et al. Incidence and clinical significance of peripheral and bone marrow basophilia. J Med. 1987;18(5-6):293–303. PubMed PMID: 3505257.
   PubMedGoogle Scholar
• Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011 Jul 21;118(3):686–692. doi:10.1182/blood-2010-12-319038. PubMed PMID: 21536864. doi: 10.1182/blood-2010-12-319038
   PubMed Web of Science ®Google Scholar
• Hasford J, Pfirrmann M, Hehlmann R, et al. A new prognostic score for survival of patients with chronic myeloid leukemia treated with interferon alfa. Writing committee for the collaborative CML prognostic factors project group. J Natl Cancer Inst. 1998 Jun 03;90(11):850–858. PubMed PMID: 9625174. doi: 10.1093/jnci/90.11.850
   PubMedGoogle Scholar
• Braga GW, Chauffaille ML, Moncau JE, et al. Chronic myeloid leukemia (CML): prognostic factors and survival analysis. Sao Paulo Med J. 1996 Jan-Feb;114(1):1083–1090. PubMed PMID: 8984584. doi: 10.1590/S1516-31801996000100005
   PubMedGoogle Scholar
• Steegmann J, Odriozola J, Rodriguez-Salvanes F, et al. Stage, percentage of basophils at diagnosis, hematologic response within six months, cytogenetic response in the first year: the main prognostic variables affecting outcome in patients with chronic myeloid leukemia in chronic phase treated with interferon-alpha. Results of the CML89 trial of the Spanish Collaborative Group on Interferon-alpha2a and CML. Haematologica. 1999;84(11):978–987.
   PubMed Web of Science ®Google Scholar
• Pieri L, Bogani C, Guglielmelli P, et al. The JAK2V617 mutation induces constitutive activation and agonist hypersensitivity in basophils from patients with polycythemia vera. Haematologica. 2009;94(11):1537–1545. doi:10.3324/haematol.2009.007047. PubMed PMID: PMC2770964. doi: 10.3324/haematol.2009.007047
   PubMed Web of Science ®Google Scholar
• Thiele J, Kvasnicka HM, Facchetti F, et al. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica. 2005 Aug;90(8):1128–1132. PubMed PMID: 16079113.
   PubMed Web of Science ®Google Scholar
• Baxter EJ, Scott LM, Campbell PJ, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet. 2005 Mar 19-25;365(9464):1054–1061. doi:10.1016/S0140-6736(05)71142-9. PubMed PMID: 15781101. doi: 10.1016/S0140-6736(05)74230-6
   PubMed Web of Science ®Google Scholar
• Bilbao-Sieyro C, Santana G, Moreno M, et al. High resolution melting analysis: a rapid and accurate method to detect CALR mutations. PloS one. 2014;9(7):e103511. doi:10.1371/journal.pone.0103511. PubMed PMID: 25068507; PubMed Central PMCID: PMC4113452. doi: 10.1371/journal.pone.0103511
   PubMed Web of Science ®Google Scholar
• Pardanani A, Guglielmelli P, Lasho TL, et al. Primary myelofibrosis with or without mutant MPL: comparison of survival and clinical features involving 603 patients. Leukemia. 2011 Dec;25(12):1834–1839. doi:10.1038/leu.2011.161. PubMed PMID: 21691276. doi: 10.1038/leu.2011.161
   PubMed Web of Science ®Google Scholar
• Lucijanic M, Skelin M, Lucijanic T. Survival analysis, more than meets the eye. Biochem Med. 2017 Feb 15;27(1):14–18. doi:10.11613/BM.2017.002. PubMed PMID: 28392721; PubMed Central PMCID: PMC5382852. doi: 10.11613/BM.2017.002
   Web of Science ®Google Scholar
• Lucijanic M. Survival analysis in clinical practice: analyze your own data using an excel workbook. Croat Med J. 2016 Feb 29;57(1):77–79. PubMed PMID: 26935618. doi: 10.3325/cmj.2016.57.77
   PubMed Web of Science ®Google Scholar
• Elliott MA, Verstovsek S, Dingli D, et al. Monocytosis is an adverse prognostic factor for survival in younger patients with primary myelofibrosis. Leuk Res. 2007;31(11):1503–1509. doi:10.1016/j.leukres.2006.12.025. PubMed PMID: 17397921. doi: 10.1016/j.leukres.2006.12.025
   PubMed Web of Science ®Google Scholar
• Agis H, Krauth MT, Bohm A, et al. Identification of basogranulin (BB1) as a novel immunohistochemical marker of basophils in normal bone marrow and patients with myeloproliferative disorders. Am J Clin Pathol. 2006 Feb;125(2):273–281. doi:10.1309/M9FQ-MQGF-6616-7N2X. PubMed PMID: 16393678. doi: 10.1309/M9FQMQGF66167N2X
   PubMed Web of Science ®Google Scholar
• Agis H, Krauth MT, Mosberger I, et al. Enumeration and immunohistochemical characterisation of bone marrow basophils in myeloproliferative disorders using the basophil specific monoclonal antibody 2D7. J Clin Pathol. 2006;59(4):396–402. doi:10.1136/jcp.2005.029215. PubMed PMID: 16461568; PubMed Central PMCID: PMC1860377. doi: 10.1136/jcp.2005.029215
   PubMed Web of Science ®Google Scholar
• Schroeder JT, MacGlashan DW, Jr, Lichtenstein LM. Advances in immunology. Adv Immunol. 2001;77:93–122. PubMed PMID: 11293121. doi: 10.1016/S0065-2776(01)77015-0
   PubMed Web of Science ®Google Scholar
• Stone KD, Prussin C, Metcalfe DD. Ige, mast cells, basophils, and eosinophils. J Allergy Clin Immunol. 2010;125(2 Suppl 2):S73–S80. doi:10.1016/j.jaci.2009.11.017. PubMed PMID: PMC2847274. doi: 10.1016/j.jaci.2009.11.017
   PubMed Web of Science ®Google Scholar
• Valent P, Bettelheim P. The human basophil. Crit Rev Oncol/Hematol. 1990;10:327–352. doi: 10.1016/1040-8428(90)90009-H
   PubMed Web of Science ®Google Scholar
• Soylu K, Gulel O, Yucel H, et al. The effect of blood cell count on coronary flow in patients with coronary slow flow phenomenon. Pak J Med Sci. 2014 Sep-Oct;30(5):936–941. doi:10.12669/pjms.305.4935. PubMed PMID: PMC4163207.
   PubMed Web of Science ®Google Scholar
• Chi Y, Lindgren V, Quigley S, et al. Acute myelogenous leukemia with t(6;9)(p23;q34) and marrow basophilia: an overview. Arch Pathol Lab Med. 2008 Nov;132(11):1835–1837. doi:10.1043/1543-2165-132.11.1835. PubMed PMID: 18976025.
   PubMed Web of Science ®Google Scholar
• Pearson MG, Vardiman JW, Le Beau MM, et al. Increased numbers of marrow basophils may be associated with a t(6;9) in ANLL. Am J Hematol. 1985 Apr;18(4):393–403. PubMed PMID: 3976650. doi: 10.1002/ajh.2830180409
   PubMed Web of Science ®Google Scholar
• Alsabeh R, Brynes RK, Slovak ML, et al. Acute myeloid leukemia with t(6;9) (p23;q34): association with myelodysplasia, basophilia, and initial CD34 negative immunophenotype. Am J Clin Pathol. 1997 Apr;107(4):430–437. PubMed PMID: 9124211. doi: 10.1093/ajcp/107.4.430
   PubMed Web of Science ®Google Scholar
• Hussein K, Van Dyke DL, Tefferi A. Conventional cytogenetics in myelofibrosis: literature review and discussion. Eur J Haematol. 2009 May;82(5):329–338. doi:10.1111/j.1600-0609.2009.01224.x. PubMed PMID: 19141119. doi: 10.1111/j.1600-0609.2009.01224.x
   PubMed Web of Science ®Google Scholar
• Tefferi A, Mesa RA, Schroeder G, et al. Cytogenetic findings and their clinical relevance in myelofibrosis with myeloid metaplasia. Br J Haematol. 2001 Jun;113(3):763–771. PubMed PMID: 11380468. doi: 10.1046/j.1365-2141.2001.02796.x
   PubMed Web of Science ®Google Scholar
• Caramazza D, Begna KH, Gangat N, et al. Refined cytogenetic-risk categorization for overall and leukemia-free survival in primary myelofibrosis: a single center study of 433 patients. Leukemia. 2011 Jan;25(1):82–88. doi:10.1038/leu.2010.234. PubMed PMID: 20944670; PubMed Central PMCID: PMC3035978. doi: 10.1038/leu.2010.234
   PubMed Web of Science ®Google Scholar
• Li M, Wen L, Cen J, et al. JAK2V617F allele burden in patients with myeloproliferative neoplasms carrying trisomy 9, and its relationship with clinical phenotypes. Int J Hematol. 2016 May;103(5):599–601. doi:10.1007/s12185-016-1986-2. PubMed PMID: 27084251. doi: 10.1007/s12185-016-1986-2
   PubMed Web of Science ®Google Scholar